Buy & Sell AbCellera Biologics Inc (ABCL) – AbCellera Biologics Inc Price Today
Aura AI Summary
Key Stats
- $1.72BMarket Cap
- HealthSector
- -22.86%3M Drawdown
- $1.35BEnterprise Value
- -Dividend Yield
- 93% Buy | 7% SellTrading Activity
- 39 daysTypical Hold Time
AbCellera Biologics Inc (ABCL) is currently valued at a market capitalization of $1.72B, with an enterprise value of $1.35B. Over the past 52 weeks, AbCellera Biologics Inc has traded between a low of $2.44 and a high of $6.46, highlighting its annual price range. Over the past three months, AbCellera Biologics Inc has recorded a drawdown of -22.86%, reflecting recent price volatility. On average, investors hold AbCellera Biologics Inc for approximately 39 days, indicating typical investor behavior on the platform.
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Most Recent News
Investigation launched into Verra Mobility over possible securities fraud linked to contract disclosure.
Ademi LLP is investigating Verra Mobility for potential securities fraud related to inaccurate statements about its financials and business operations. The probe centers on Verra Mobility's failure to timely disclose contract negotiations with Avis B...

Japan and Eurozone ETFs offer distinct advantages for 2026 international investing strategies.
Japan's stock market is performing strongly in 2026, driven by corporate reforms, a cautious Bank of Japan, and a weak yen. Investors can choose between the iShares MSCI Japan ETF (EWJ), which is unhedged and offers broad exposure, and the WisdomTree...

Ademi LLP investigates Via Transportation for possible securities fraud claims.
Ademi LLP has launched an investigation into Via Transportation following concerns about potential securities fraud. The investigation focuses on whether Via made inaccurate statements regarding its financials, business operations, and future prospec...
